Abstract
Contrast agents are increasingly being used in diagnostic magnetic resonance (MR) imaging to help detect and characterize pathological abnormalities. In fact, it has been estimated that nearly 50% of all MR examinations already involve the use of MR contrast agents, with chelated gadolinium compounds being by far the most widely used.[1,2] Most clinically relevant Gd-based agents are small, non-targeted compounds that passively distribute into the intravascular and interstitial space.[3] However, there has recently been emerging interest in the development of paramagnetic contrast agents that are capable of probing the molecular profile of tissues via ligand targeting, enzymatic activity and multiplexing.[4,5] It is envisioned that these agents could be used to acquire a more specific clinical diagnosis and thus improve patient management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
